Applied DNA - APDN Forward P/S Multiple
Applied DNA Sciences (APDN) profitability remains low due to high capital burn associated with product promotion. The company's projected P/S reflects market expectations, where 2.20 determines the latest valuation metric. Long-term contracts for cargo anti-counterfeiting and the implementation of automated AI platforms for DNA synthesis, which minimize production defects, provide positive catalysts.
Summary analytical data breakdowns for Applied DNA Corp (APDN)
- market price and analyst price targets:
- issuer market value details:
- issuer book value statistics:
- issuer credit burden and liquidity indicators:
Total Debt to Capital Applied DNA Sciences|APDN - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital Applied DNA Sciences|APDN - Company Total Debt Obligations|Debts to Book Capitalization Applied DNA Corp|APDN - Long-Term Debt|Company Short-Term Debt Applied DNA Sciences|Quick Ratio adnas.com
- net income and valuation multiples indicators:
APDN - Net Income|Projected Future Earnings Applied DNA Sciences|APDN - Market Cap to Earnings|Future Price to Earnings Applied DNA|APDN - Growth-Adjusted Market Cap to Net Income|EV/EBITDA Multiple Applied DNA Corp|APDN - Operating profit EBITDA|Earnings per share for the last twelve months Applied DNA Sciences|APDN - Earnings per one share for the last 12 months|Quarterly EPS earnings growth adnas.com|APDN - Earnings per share growth this year|Net earnings per share growth forecast for next year Applied DNA Sciences
- company sales and revenue statistics:
Comprehensive company analysis:Applied DNA Sciences, Inc. APDN
Forward P/S links current market capitalization to expected revenue, allowing an investor to assess the value of one dollar of projected sales. An analysis of the forward P/S for Applied DNA Sciences (APDN) reveals whether the asset is overbought or undervalued, which is critical for Applied DNA Sciences (APDN), as its scalability through automated DNA marking and synthesis robotics must translate into exponential growth in future revenues.
Competitor analysis
Price-to-Projected Revenue Ratio Tempus AI, Inc. TEM|QGEN: Market Cap to Projected Revenue|Ionis Pharma - Forward P/S Multiple|RGEN - Forward P/S Multiple|RNA (Avidity Biosciences) - Forward Price-to-Revenue Multiple|crisprtx.com - Forward Price to Sales|Price-to-Projected Revenue Ratio GeneDx|Ultragenyx Pharmaceutical Inc. (RARE) - Market Cap to Expected Sales Ratio|Forward P/S Multiple BEAM|Forward Price-to-Revenue Multiple Sarepta Corp SRPT|Forward P/S Multiple TWST (Twist Bioscience)|Market Cap to Expected Sales Ratio 10xgenomics.com (TXG)|Intellia Therapeutics, Inc. - Forward P/S Multiple|Market Cap to Future Revenue Ratio Stoke Therapeutics Inc|BioLife Corp (BLFS) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue WVE|MAZE (Maze Therapeutics Inc) - Forward P/S Multiple|Forward Price-to-Revenue Multiple sionnatx.com (SION)|Forward P/S Multiple PRME|TSHA - Market Cap to Future Revenue Ratio|Price-to-Projected Revenue Ratio uniQure Corp QURE|Market Cap to Expected Sales Ratio MeiraGTx Corp (MGTX)|REGENXBIO Inc. - Forward P/S Multiple|SLDB - Forward P/S Multiple|Ocugen (OCGN) - Price-to-Projected Revenue Ratio|Future Price to Revenue PACB (Pacific Biosciences of California, Inc.)|BNTC (Benitec) - Forward P/S Multiple|Market Cap to Projected Revenue DSGN (Design Corp)|Price-to-Projected Revenue Ratio Rocket Pharmaceuticals (RCKT)|4dmoleculartherapeutics.com - Market Cap to Projected Revenue|Forward P/S Multiple LXEO (Lexeo Therapeutics, Inc.)|KRRO: Market Cap to Projected Revenue|EDIT - Price-to-Projected Revenue Ratio|SLN (Silence Therapeutics Corp) - Market Cap to Projected Revenue|PRQR: Forward P/S Multiple|Codexis (CDXS) - Forward P/S Multiple|SGMO (Sangamo Therapeutics, Inc.) - Forward P/S Multiple|Forward P/S Multiple Nautilus Biotechnology Inc|Price-to-Projected Revenue Ratio Metagenomi, Inc (MGX)|DTIL: Future Price to Revenue|Price-to-Projected Revenue Ratio Generation Bio GBIO|BOLD (boundlessbio.com) - Future Price to Revenue|XCUR - Price-to-Projected Revenue Ratio|IMNN: Price-to-Projected Revenue Ratio|PHIO: Forward P/S Multiple|MBIO - Market Cap to Expected Sales Ratio|RNAZ (TransCode Therapeutics Inc.) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Bionano BNGO|Forward P/S Multiple BLUE|immunoprecise.com - Market Cap to Projected Revenue|Omega - Forward Price-to-Revenue Multiple|Forward Price to Sales OMIC|Regulus Therapeutics - Forward P/S Multiple|SYRS (syros.com) - Market Cap to Projected Revenue|Telesis Bio (TBIO) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue TCON|UBX (Unity Bio) - Forward P/S Multiple
